Skip to main content

In addition to the traditional considerations associated with tax-advantaged investing, writes John Davies, investment director at Seneca Partners, advisers and their clients now need to factor in such issues as the Patient Capital Review and, yes, Brexit.

Click here for the full article.

For further information on Seneca range of product, please send us as email or callus on 020 7071 3920.

Get in Touch

Please do not hesitate to get in touch for further information on LightTower Partners or on the investment products we distribute.

Back to top